<DOC>
	<DOCNO>NCT02256917</DOCNO>
	<brief_summary>The rationale study fine-tune individualize prophylactic treatment patient severe Haemophilia A goal keep trough FVIII level 1 % dos . Because trough FVIII level likely important predictor efficacy prophylaxis , focus study PK data .</brief_summary>
	<brief_title>Assess Efficacy Safety Personalized Prophylaxis Human-cl rhFVIII Patients With Severe Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe Haeomophilia A ( FVIII : C &lt; 1 % ) Male patient &gt; = 18 year age Previous treatment FVIII concentrate least 150 EDs Good documentation regard dose bleeding frequency 6 month precede study start Immunocompetence ( CD4+ cound &gt; 200/ul ) Any coagulation disorder Haemophilia A Present past FVIII inhibitor activity Severe liver kidney disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>